SEARCH

SEARCH BY CITATION

References

  • 1
    Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118: S68S82.
  • 2
    Bjorck S, Dahlstrom A, Johansson L, Ahlman H. Treatment of the mucosa with local anaesthetics in ulcerative colitis. Agents Actions 1992; C6072.
  • 3
    Bjorck S, Dahlstrom A, Ahlman H. Topical treatment of ulcerative proctitis with lidocaine. Scand J Gastroenterol 1989; 24: 10611072.
  • 4
    Hammer R, Dahlgren C, Stendahl O. Inhibition of human leukocyte metabolism and random mobility by local anaesthesia. Acta Anaesthesiol Scand 1985; 29: 520523.
  • 5
    Martinsson T, Oda T, Fernvik E, Roempke K, Dalsgaard CJ, Svensjo E. Ropivacaine inhibits leukocyte rolling, adhesion and CD11b/CD18 expression. J Pharm Exp Ther 1997; 283: 5965.
  • 6
    Martinsson T, Ljung T, Rubio C, Hellstrom PM. Beneficial effects of ropivacaine in rat experimental colitis. J Pharm Exp Ther 1999; 291: 642647.
  • 7
    Martinsson T, Haegerstrand A, Dalsgaard CJ. Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro. Inflamm Res 1997; 46: 398403.
  • 8
    Martinsson T. Ropivacaine inhibits serum-induced proliferation of colon adenocarcinoma cells in vitro. J Pharm Exp Ther 1999; 288: 660664.
  • 9
    De Boer AG, Breimer DD. Drug absorption: portal or sytemic? In Proceedings of the Edinburgh International Conference. Eds PrescottLF, NimmoWM. Sydney: ADIS Press, 1981; 6172.
  • 10
    Steed KP, Wilson CG, Washington N. Drug delivery to the large intestine. In Physiological Pharmaceutics. Biological Barriers to Drug Absorption. Eds WilsonCG, WashingtonN. Chichester: Ellis Horwood Ltd, 1989; 91108.
  • 11
    McClure JH. Ropivacaine. Br J Anaesth 1996; 76: 300307.
  • 12
    Arvidsson T, Bruce HF, Halldin MM. Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column. Chirality 1995; 7: 272277.
  • 13
    Emanuelsson BM, Persson J, Sandin S, Alm C, Gustafsson LL. Intraindividual and interindividual variability in the disposition of the local anesthetic ropivacaine in healthy subjects. Ther Drug Monit 1997; 19: 126131.
  • 14
    Arlander E, Ekstrom G, Alm C et al. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998; 64: 484491.
  • 15
    Ekstrom G, Gunnarsson UB. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996; 24: 955961.
  • 16
    Bertilsson L, Lou YQ, Du YL et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin[published erratum appears in Clin Pharmacol Ther 1994; 55: 648]. Clin Pharmacol Ther 1992; 51: 388397.
  • 17
    Sjovall J, Westerlund D, Alvan G, Magni L, Nord CE, Sorstad J. Rectal bioavailability of bacampicillin hydrochloride in man as determined by reversed-phase liquid chromatography. Chemotherapy 1984; 30: 137147.
  • 18
    Bjork M, Pettersson KJ, Osterlof G. Capillary gas chromatographic method for the simultaneous determination of local anaesthetics in plasma samples. J Chromatogr 1990; 533: 229234.
  • 19
    Engman M, Neidenstrom P, Norsten-Hoog C, Wiklund SJ, Bondesson U, Arvidsson T. Determination of ropivacaine and [2H3]ropivacaine in biological samples by gas chromatography with nitrogen-phosphorus detection or mass spectrometry. J Chromatogr B, Biomed Sci Applications 1998; 709: 5767.
  • 20
    Arvidsson T, Askemark Y, Halldin MM. Liquid chromatographic bioanalytical determination of ropivacaine, bupivacaine and major metabolites. Biomed Chromatogr 1999; 13: 286292.
  • 21
    Rowland M, Tozer TN. In Clinical Pharmacokinetics. Concepts and Applications. Philadelphia: Williams & Wilkins, 1995.
  • 22
    Loo JC, Riegelman S. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 1968; 57: 918928.
  • 23
    Graybill FA. Theory and Linear Application of the Linear Model. North Scituate, Massachusetts: Duxbury: 1976; 606621.
  • 24
    Gough K, Hutchison M, Keene O et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inform J 1995; 29: 10391048.
  • 25
    Convery PN, Milligan KR, Quinn P, Sjövall J, Gustafsson U. Efficacy and uptake of ropivacaine and bupivacaine after single intra-articular injection in the knee joint. Br J Anaesthesia 2001; 87: 570576.
  • 26
    Gjellan K, Graffner C. Influence of amount of hard fat in suppositories on the in vitro release rate and bioavailability of paracetamol II. A comparison between three compositions and a rectal solution. Int J Pharm 1994; 104: 215226.
  • 27
    Bannister LH. Alimentary system. In Gray's Anatomy, 38th edn, ed. WilliamsPL. New York: Churchill Livingstone, 1995; 17771778.
  • 28
    De Leede LGJ, De Boer AG, Feijen CD, Breimer DD. Site specific rectal drug administration in man with an osmotic system. Influence on ‘first-pass’ elimination of lidocaine. Pharm Res 1984; 3: 129134.
  • 29
    Campieri M, Lanfranchi GA, Boschi S et al. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut 1985; 26: 400405.
  • 30
    Edwards CA. Anatomical and physiological basis: physiological factors influencing drug absorption. In Colonic Drug Absorption and Metabolism, ed. BieckPR. New York: Marcel Dekker, Inc., 1993; 128.
  • 31
    Arlander E, Ost A, Stahlberg D, Lofberg R. Ropivacaine gel in active distal ulcerative colitis and proctitis—a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996; 10: 7381.
  • 32
    Emanuelsson BM, Persson J, Alm C, Heller A, Gustafsson LL. Systemic absorption and block after epidural injection of ropivacaine in healthy volunteers. Anesthesiology 1997; 87: 13091317.
  • 33
    Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB. Disposition kinetics of ropivacaine in humans. Anesth Analg 1989; 69: 736738.
  • 34
    Emanuelsson BM, Norsten-Höög C, Sandberg R, Sjövall J. Ropivacaine and its 2H3-labelled analogue—bioanalysis and disposition in healthy volunteers. Eur J Pharm Sci 1997; 5: 171177.
  • 35
    Halldin MM, Bredberg E, Angelin B et al. Metabolism and excretion of ropivacaine in humans. Drug Metab Dispos 1996; 24: 962968.
  • 36
    Scott DB. Toxic effects of local anaesthetic agents on the central nervous system. Br J Anaesth 1986; 58: 732735.
  • 37
    Scott DB, Lee A, Fagan D, Bowler GM, Bloomfield P, Lundh R. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563569.
  • 38
    Knudsen K, Beckman Suurkula M, Blomberg S, Sjovall J, Edvardsson N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997; 78: 507514.